ClinicalTrials.gg
TerminatedNCT04162470Updated Jun 12, 2023Results posted

REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate Its Long Term Safety, Efficacy and Tolerability.

A Phase 3 interventional study of REGN3918 in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Regeneron Pharmaceuticals. Terminated at 14 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-12.

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment

Why this study was terminated
Business Decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals — 3 open to participants now, 3 under way, 2 of them phase 3. Hemoglobinuria, Paroxysmal · Regeneron Pharmaceuticals.

Started
2019
with 1 other
Phase 3
5 of 10
2 open now
Registered
2nd of 10
by date

Among the 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals, this one is one of 2 that started in 2019, is one of 5 in phase 3, and was the 2nd registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

3 of the 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the long-term safety, tolerability, and effect on intravascular hemolysis of REGN3918 in patients with paroxysmal nocturnal hemoglobinuria (PNH).

The secondary objectives of the study are:

  • To evaluate the long-term effect of REGN3918 on intravascular hemolysis
  • To assess the concentrations of total REGN3918 in serum
  • To evaluate the occurrence of the immunogenicity of REGN3918
03

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria

Keywords

  • PNH
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Patients with PNH who have completed, without discontinuation, study treatment in one of the parent studies in which they participated (either R3918-PNH-1852 [NCT03946748] or R3918-PNH-1853)

Key Exclusion Criteria:

  • Significant protocol deviation(s) in the parent study based on the investigator's judgment and to the extent that these would (if continued) impact the study objectives and/or safety of the patient (for example, repetitive non-compliance with dosing by the patient)
  • Any new condition or worsening of an existing condition which, in the opinion of the investigator, would make the patient unsuitable for enrollment or could interfere with the patient participating in or completing the study

NOTE: Other protocol defined exclusion criteria apply

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    REGN3918

    Participants who have completed 1 of the 2 parent studies (R3918-PNH-1852 \[NCT03946748\] or R3918-PNH-1853)

    Drug: REGN3918

Interventions

  • Subcutaneous (SC) every week (QW) over the treatment period

    Also known as: Pozelimab

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

    An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. TEAEs was defined as AEs that developed or worsened during the on-treatment period. SAE was defined as any untoward medical occurrence that resulted in any of following outcomes: death, life-threatening, required initial/prolonged in-participant hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect/considered as medically important event. TEAEs included both Serious TEAEs and non-serious TEAEs.

    Time frame: Baseline up to Week 104

  2. Percentage of Participants Who Achieved Lactate Dehydrogenase (LDH) Less Than or Equal to (≤) 1.5* ULN From Baseline to Week 26

    Percentage of participants who achieved LDH ≤1.5\* Upper limit of normal (ULN) over Week 26, defined as LDH ≤1.5\*ULN from baseline up to Week 26 were reported. A participant was considered to have met the criteria for adequate control of intravascular hemolysis if all of their LDH readings from the baseline through Week 26 inclusive or through the analysis end date, whichever is earlier, had values ≤ 1.5\*ULN.

    Time frame: Baseline up to Week 26

Secondary outcomes

  1. Percentage of Participants Who Had Breakthrough Hemolysis Through Week 26 and 78

    A participant was considered to have breakthrough hemolysis if he/she had any LDH measurement greater than or equal to (≥) 2\*ULN, concomitant with associated signs or symptoms at any time subsequent to an initial achievement of disease control (i.e., LDH ≤ 1.5\* ULN).

    Time frame: At Week 26 and 78

  2. Overall Rate of Transfusion With Red Blood Cell (RBCs) Through Week 26

    The overall rate of transfusion for a participant was calculated based on the duration of treatment exposure of the participant.

    Time frame: Baseline up to Week 26

  3. Percentage of Participants Who Are Transfusion-free (With RBCs) Through Week 26 and 78

    Transfusion free was defined as not having received an RBC transfusion during the first 26 and 78 weeks. A transfusion was counted only if it was per-protocol, that is, if it follows the predefined transfusion algorithm: RBC transfusion due to a post-baseline hemoglobin level less than (\<) 9 gram per deciliter (g/dL) (with anemia symptoms) or a post-baseline hemoglobin level \< 7 g/dL (without anemia symptoms).

    Time frame: At Week 26 and 78

  4. Percentage of Participants Who Achieved Adequate Control of Intravascular Hemolysis Through Week 78

    A participant was considered to have met the criteria for adequate control of intravascular hemolysis if all of his/her LDH readings from the baseline through Week 78 inclusive or through the analysis end date, whichever is earlier, had values \<=1.5\* ULN. and must not have discontinued study treatment early.

    Time frame: Baseline up to Week 78

  5. Percentage of Participants Who Achieved Normalization of Intravascular Hemolysis Through Week 26 and Week 78

    A participant was considered to have met normalization of intravascular hemolysis if all of their LDH readings from the baseline through Week 26 or 78 inclusive, or through the analysis end date, whichever is earlier, had values ≤ 1.0\*ULN.

    Time frame: Baseline, Week 26 and 78

  6. Changes From Baseline in LDH Levels at Week 26, 78, and 104

    Change from baseline in LDH levels at Week 26, 78, and 104 was reported. Reported baseline is from R3918-PNH-1852 study.

    Time frame: Baseline, Week 26, 78, and 104

  7. Percent Change From Baseline in LDH Levels at Week 26, 78, and 104

    Percent change from baseline in LDH levels at Week 26, 78, and 104 was reported. Reported baseline is from R3918-PNH-1852 study.

    Time frame: Baseline, Week 26, 78, and 104

  8. Change From Baseline in Red Blood Cell (RBC) Hemoglobin Levels at Week 26, 78, and 104

    Change from baseline in RBC hemoglobin levels at Week 26, 78, and 104 was reported.

    Time frame: Baseline, Week 26, 78, and 104

  9. Change From Baseline in Free Hemoglobin Levels at Week 26, 78 and 104

    Change from baseline in free hemoglobin levels at Week 26, 78 and 104 was reported.

    Time frame: Baseline, Week 26, 78 and 104

  10. Serum Concentrations of Total REGN3918

    Serum Concentrations of total REGN3918 was reported.

    Time frame: Pre-dose (Day 1), End of infusion at Week 13, 26, 39, 52, 65, 78, 91 and 104

  11. Number of Participants With Treatment-emergent Anti-Drug Antibodies (ADA) to REGN3918

    Number of Participants with treatment-emergent ADA response to REGN3918 was reported. The ADA analysis set (AAS) includes all treated participants who received any amount of study drug (active \[SAF\]) and had at least 1 non missing anti pozelimab antibody result following the first dose of study drug. The AAS is based on the actual treatment received (as treated).

    Time frame: Baseline up to Week 104

07

Results

Posted Jun 12, 2023

Participant flow

Participant flow — Overall Study
MilestoneREGN3918
Started24
Completed0
Not completed24
Withdrew: Withdrawn due to sponsor's decision24

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. TEAEs was defined as AEs that developed or worsened during the on-treatment period. SAE was defined as any untoward medical occurrence that resulted in any of following outcomes: death, life-threatening, required initial/prolonged in-participant hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect/considered as medically important event. TEAEs included both Serious TEAEs and non-serious TEAEs.

Time frame:
Baseline up to Week 104
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
ParticipantsREGN3918
Participants with TEAEs15
Participants with Serious TEAEs2
PrimaryPercentage of Participants Who Achieved Lactate Dehydrogenase (LDH) Less Than or Equal to (≤) 1.5* ULN From Baseline to Week 26

Percentage of participants who achieved LDH ≤1.5\* Upper limit of normal (ULN) over Week 26, defined as LDH ≤1.5\*ULN from baseline up to Week 26 were reported. A participant was considered to have met the criteria for adequate control of intravascular hemolysis if all of their LDH readings from the baseline through Week 26 inclusive or through the analysis end date, whichever is earlier, had values ≤ 1.5\*ULN.

Time frame:
Baseline up to Week 26
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Lactate Dehydrogenase (LDH) Less Than or Equal to (≤) 1.5* ULN From Baseline to Week 26
Percentage of participantsREGN3918
Percentage of Participants Who Achieved Lactate Dehydrogenase (LDH) Less Than or Equal to (≤) 1.5* ULN From Baseline to Week 2695.7 (87.3 to 100.0)
SecondaryPercentage of Participants Who Had Breakthrough Hemolysis Through Week 26 and 78

A participant was considered to have breakthrough hemolysis if he/she had any LDH measurement greater than or equal to (≥) 2\*ULN, concomitant with associated signs or symptoms at any time subsequent to an initial achievement of disease control (i.e., LDH ≤ 1.5\* ULN).

Time frame:
At Week 26 and 78
Reported as:
Number · Percentage of participants
Percentage of Participants Who Had Breakthrough Hemolysis Through Week 26 and 78
Percentage of participantsREGN3918
At Week 260 (0 to 0)
At Week 780 (0 to 0)
SecondaryOverall Rate of Transfusion With Red Blood Cell (RBCs) Through Week 26

The overall rate of transfusion for a participant was calculated based on the duration of treatment exposure of the participant.

Time frame:
Baseline up to Week 26
Reported as:
Number · Transfusion per person-year of treatment
Overall Rate of Transfusion With Red Blood Cell (RBCs) Through Week 26
Transfusion per person-year of treatmentREGN3918
Overall Rate of Transfusion With Red Blood Cell (RBCs) Through Week 260.164 (0.006 to 4.678)
SecondaryPercentage of Participants Who Are Transfusion-free (With RBCs) Through Week 26 and 78

Transfusion free was defined as not having received an RBC transfusion during the first 26 and 78 weeks. A transfusion was counted only if it was per-protocol, that is, if it follows the predefined transfusion algorithm: RBC transfusion due to a post-baseline hemoglobin level less than (\<) 9 gram per deciliter (g/dL) (with anemia symptoms) or a post-baseline hemoglobin level \< 7 g/dL (without anemia symptoms).

Time frame:
At Week 26 and 78
Reported as:
Number · Percentage of participants
Percentage of Participants Who Are Transfusion-free (With RBCs) Through Week 26 and 78
Percentage of participantsREGN3918
At Week 2695.7 (87.3 to 100.0)
At Week 7893.8 (81.9 to 100.0)
SecondaryPercentage of Participants Who Achieved Adequate Control of Intravascular Hemolysis Through Week 78

A participant was considered to have met the criteria for adequate control of intravascular hemolysis if all of his/her LDH readings from the baseline through Week 78 inclusive or through the analysis end date, whichever is earlier, had values \<=1.5\* ULN. and must not have discontinued study treatment early.

Time frame:
Baseline up to Week 78
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Adequate Control of Intravascular Hemolysis Through Week 78
Percentage of participantsREGN3918
Percentage of Participants Who Achieved Adequate Control of Intravascular Hemolysis Through Week 7893.8 (81.9 to 100.0)
SecondaryPercentage of Participants Who Achieved Normalization of Intravascular Hemolysis Through Week 26 and Week 78

A participant was considered to have met normalization of intravascular hemolysis if all of their LDH readings from the baseline through Week 26 or 78 inclusive, or through the analysis end date, whichever is earlier, had values ≤ 1.0\*ULN.

Time frame:
Baseline, Week 26 and 78
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Normalization of Intravascular Hemolysis Through Week 26 and Week 78
Percentage of participantsREGN3918
At Week 2675.0 (57.7 to 92.3)
At Week 7855.0 (33.2 to 76.8)
SecondaryChanges From Baseline in LDH Levels at Week 26, 78, and 104

Change from baseline in LDH levels at Week 26, 78, and 104 was reported. Reported baseline is from R3918-PNH-1852 study.

Time frame:
Baseline, Week 26, 78, and 104
Reported as:
Mean · Units per liter (U/L)
Changes From Baseline in LDH Levels at Week 26, 78, and 104
Units per liter (U/L)REGN3918
At Week 26-5.098 ± 2.5695
At Week 78-5.395 ± 2.8468
At Week 104-5.270 ± 2.9057
SecondaryPercent Change From Baseline in LDH Levels at Week 26, 78, and 104

Percent change from baseline in LDH levels at Week 26, 78, and 104 was reported. Reported baseline is from R3918-PNH-1852 study.

Time frame:
Baseline, Week 26, 78, and 104
Reported as:
Mean · Percent change
Percent Change From Baseline in LDH Levels at Week 26, 78, and 104
Percent changeREGN3918
At Week 26-81.900 ± 8.9226
At Week 78-84.256 ± 8.1412
At Week 104-83.930 ± 7.6705
SecondaryChange From Baseline in Red Blood Cell (RBC) Hemoglobin Levels at Week 26, 78, and 104

Change from baseline in RBC hemoglobin levels at Week 26, 78, and 104 was reported.

Time frame:
Baseline, Week 26, 78, and 104
Reported as:
Mean · Gram per liter (g/l)
Change From Baseline in Red Blood Cell (RBC) Hemoglobin Levels at Week 26, 78, and 104
Gram per liter (g/l)REGN3918
At Week 263.6 ± 8.97
At Week 785.3 ± 17.20
At Week 104-2.4 ± 16.56
SecondaryChange From Baseline in Free Hemoglobin Levels at Week 26, 78 and 104

Change from baseline in free hemoglobin levels at Week 26, 78 and 104 was reported.

Time frame:
Baseline, Week 26, 78 and 104
Reported as:
Mean · Milligram per deciliter (mg/dL)
Change From Baseline in Free Hemoglobin Levels at Week 26, 78 and 104
Milligram per deciliter (mg/dL)REGN3918
At Week 26-1.39 ± 6.929
At Week 78-0.56 ± 2.196
At Week 104-0.93 ± 1.153
SecondarySerum Concentrations of Total REGN3918

Serum Concentrations of total REGN3918 was reported.

Time frame:
Pre-dose (Day 1), End of infusion at Week 13, 26, 39, 52, 65, 78, 91 and 104
Reported as:
Mean · Milligrams per liter (mg/L)
Serum Concentrations of Total REGN3918
Milligrams per liter (mg/L)REGN3918
Pre-dose (Day 1)423 ± 218
Week 13398 ± 203
Week 26401 ± 212
Week 39420 ± 216
Week 52413 ± 202
Week 65438 ± 207
Week 78433 ± 266
Week 91483 ± 278
SecondaryNumber of Participants With Treatment-emergent Anti-Drug Antibodies (ADA) to REGN3918

Number of Participants with treatment-emergent ADA response to REGN3918 was reported. The ADA analysis set (AAS) includes all treated participants who received any amount of study drug (active \[SAF\]) and had at least 1 non missing anti pozelimab antibody result following the first dose of study drug. The AAS is based on the actual treatment received (as treated).

Time frame:
Baseline up to Week 104
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Anti-Drug Antibodies (ADA) to REGN3918
ParticipantsREGN3918
Number of Participants With Treatment-emergent Anti-Drug Antibodies (ADA) to REGN39180

Adverse events

Collected over From first dose to Week 104. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
REGN39180/24 (0%)2/24 (8.3%)6/24 (25%)
Most frequent serious events
Most frequent serious events
EventREGN3918
Abdominal painGastrointestinal disorders1/24
InfluenzaInfections and infestations1/24
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/24
Most frequent other events
Most frequent other events
EventREGN3918
Mouth ulcerationGastrointestinal disorders2/24
ChillsGeneral disorders2/24
HeadacheNervous system disorders2/24
RashSkin and subcutaneous tissue disorders2/24

Baseline characteristics

Safety Analysis Set (SAF) included all enrolled participants who received any study drug.

Age, Continuous
Age, Continuous(Years)REGN3918
Mean45.8 ± 17.26
Sex: Female, Male
Sex: Female, Male(Participants)REGN3918
Female11
Male13
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)REGN3918
Hispanic or Latino0
Not Hispanic or Latino24
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)REGN3918
American Indian or Alaska Native0
Asian21
Native Hawaiian or Other Pacific Islander0
Black or African American0
White2
More than one race0
Unknown or Not Reported1
08

Study locations

14 sites
  • Regeneron Study Site
    Sha Tin, Hong Kong
  • Regeneron Study Site
    Budapest, 1907, Hungary
  • Regeneron Study Site
    Busan, 49241, Korea, Republic of
  • Regeneron Study Site
    Seoul, 03080, Korea, Republic of
  • Regeneron Study Site
    Seoul, 03722, Korea, Republic of
  • Regeneron Study Site
    Seoul, 05030, Korea, Republic of
  • Regeneron Study Site
    Seoul, 06351, Korea, Republic of
  • Regeneron Study Site
    Seoul, 07985, Korea, Republic of
  • Regeneron Study Site
    Miri, Sarawak 98000, Malaysia
  • Regeneron Study Site
    Sibu, Sarawak 96000, Malaysia
  • Regeneron Study Site
    Kuala Terengganu, Terengganu 20400, Malaysia
  • Regeneron Study Site
    Taipei City, 10002, Taiwan
  • Regeneron Study Site
    Taoyuan City, 333, Taiwan
  • Regeneron Study Site
    Leeds, LS97TF, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.

Access criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency [EMA], Pharmaceuticals and Medical Devices Agency [PMDA], etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2019 to primary completion in Apr 2022, 28 months.

Results were first posted in Jun 2023, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2019
First posted
Nov 14, 2019
StartActual
Dec 3, 2019
Primary completionActual
Apr 7, 2022
CompletionActual
Apr 7, 2022
Results first posted
Jun 12, 2023
Last update
Jun 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04162470
Responsible party
Sponsor
First posted
Nov 14, 2019
Start date
Dec 3, 2019
Primary completion
Apr 7, 2022
Completion
Apr 7, 2022
Results posted
Jun 12, 2023
Last update
Jun 12, 2023

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pozelimab

Start the discussion